Use of Anti-il-17RB antibody or antigen-binding fragment thereof or composition
An anti-IL-17RB antibody with specific CDR sequences addresses the need for improved treatment of FLG-related diseases by restoring filaggrin expression and enhancing skin barrier function, providing faster and more effective relief in atopic dermatitis.
Patent Information
- Application Number
- AU2023475632
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-12-05
- Publication Date
- 2026-07-23
AI Technical Summary
There is a need for more effective treatment options for skin diseases associated with filaggrin downregulation, such as atopic dermatitis, as current treatments often have limitations in efficacy and long-term use due to side effects.
The use of an anti-IL-17RB antibody or its antigen-binding fragment, specifically designed with certain CDR sequences, to restore filaggrin expression and improve skin barrier function by inhibiting IL-17RB signaling and reducing ILC2 populations, thereby treating FLG-related diseases.
The anti-IL-17RB antibody effectively alleviates skin inflammation, restores filaggrin expression, and improves skin barrier function, offering faster and more significant relief in atopic dermatitis compared to existing treatments like upadacitinib.